The clinical programme comprises a first-in-human Gamma-delta T cell activating antibody.
The company raised $86m (€80m) in the Series C financing round and another $17.2m (€16m) in the last outstanding tranche of Series B converted in Series C shares.
New investors Invus and The Leukemia & Lymphoma Society Therapy Acceleration Program also participated in the financing round.
Current investors including the Growth Opportunity Fund of founding investor Kurma Partners, Eurazeo, Gimv, EQT Life Sciences, Boehringer Ingelheim Venture Fund and Pfizer Ventures among others took part.
The proceeds from the funding will be utilised to support the Phase IIa expansion arms of EVICTION in solid tumours and hematologic cancers.
Additionally, the capital will be used to conclude the randomised, double-blind, placebo-controlled clinical trials of its anti-butyrophilin 3A antibody candidate, ICT01, plus a PD-1 inhibitor for multiple solid tumours.
Furthermore, the company intends to use the funds to analyse ICT01 plus other therapeutic agents, including IL-2, in the upcoming EVICTION-2 clinical trial.
The proceeds will also aid in expediting the additional antibody candidates in immuno-oncology, auto-immune and infectious diseases into clinical trials.
It will aid the company to attain pivotal trial preparedness for ICT01 and grow its footprint in the US and Europe, through expanded clinical operations and regulatory affairs.
As part of the financing, Florent Gros from Earlybird and Raphaël Wisniewski Andera Partners will become part of the board of directors of ImCheck.
ImCheck Therapeutics CEO Pierre d’Epenoux said: “We view our singular proprietary position with butyrophilins, which offer powerful immunomodulation of both the innate and adaptive immune systems, as the key to therapeutic intervention for many disease indications and we value the support we are now gaining from The Leukemia & Lymphoma Society Therapy Acceleration Program as a first investment from a cancer patient nonprofit organisation.”